Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2. (1st January 2017)

• Record Type: Journal Article
• Authors: Iyengar, S. S.; Puri, R.; Narasingan, S. N.; Nair, D. R.; Mehta, V.; Mohan, J. C.; Wangnoo, S. K.; Dalal, J. J.; Jha, V.; Puri, S.; Misra, A.; Daga, M. K.; Varma, M.; Jasuja, S.; Upadhyaya, S.; Kasliwal, R. R.; Bansal, M.; Mehrotra, R.; Jain, A.; Talwar, K. K.; Rajput, R.; Pradhan, A.; Seth, S.; Kapoor, D.; Melinkeri, R. P.; Ramakrishnan, S.; Khanna, N. N.; Khadgawat, R.; Puri, S.; Shaikh, A.; Kovalipati, N.; Bordoloi, N.; Zargar, A. H.; Agarwal, R. K.; Rastogi, A.; Chag, M.; Prabhakar, D.; Mathur, S. K.; Rehan, H.; Sahoo, P. K.; Dutta, A.; Sharma, A.; Pancholia, A. K.; Natarajan, K. U.; Mishra, A.; Singh, K.;
• Is Part Of: Clinical lipidology. Volume 12:Number 1(2017)
• Page Start: 56
• Page End: 109
• Publication Date: 2017-01-01
• Subjects: Recommendation -- lipids -- specific populations -- India; 4D: Die Deutsche Diabetes Dialyses Studie -- ABCD: Amsterdam Born Children and Their Development -- ACC: American College of Cardiology -- ACCF: American College of Cardiology Foundation -- ACCORD: Action to Control Cardiovascular Risk in Diabetes -- AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention study -- AHA: American Heart Association -- AIM-HIGH: Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglyceride -- ALA: Alpha Linolenic Acid -- ALERT: Assessment of Lescol in Renal Transplantation -- ALT: Alanine Aminotransferase -- AST: Aspartate Aminotransferase -- Apo A: Apolipoprotein A -- Apo B: Apolipoprotein B -- Apo C: Apolipoprotein C -- Apo E: Apolipoprotein E -- AS: Ankylosing Spondylitis -- ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm -- ASCVD: Atherosclerotic Cardiovascular Disease -- AURORA: A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events -- bDMARDs: Biological Disease Modifying Anti-Rheumatic Drugs -- BNP: Brain Natriuretic Peptide -- CAD: Coronary Artery Disease -- CARDS: Collaborative Atorvastatin Diabetes Study -- CARE: Cholesterol and Recurrent Events -- CAV: Cardiac Allograft Vasculopathy -- cDMARDs: Conventional Disease Modifying Anti-Rheumatic Drugs -- CETP: Cholesteryl Ester Transfer Protein -- cIMT: Carotid Intima Media Thickness -- CK: Creatine Kinase -- CKD: Chronic Kidney Disease -- Co-Q10: Coenzyme Q10 -- CORONA: Controlled Rosuvastatin Multinational Study in Heart Failure -- COX-2: Cyclooxygenase-2 -- CRP: C-Reactive Protein -- csDMARDs: Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs -- CTT: Cholesterol Treatment Trialists' -- CV: Cardiovascular -- CVD: Cardiovascular Disease -- DHA: Docosahexaenoic Acid -- DM: Diabetes Mellitus -- DMARDs: Disease Modifying Anti-Rheumatic Drugs -- DOPPS: Dialysis Outcome and Practice Patterns Study -- eGFR: Estimated Glomerular Filtration Rate -- EPA: Eicosapentaenoic Acid -- ESRD: End Stage Renal Disease -- FH: Familial Hypercholesterolaemia -- FDA: Food and Drug Administration -- FOURIER: Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk -- FIELD: Fenofibrate Intervention and Event Lowering in Diabetes -- GISSI-HF: GruppoItaliano per lo Studio dellaSopravvivenzanell'InfartoMiocardico Heart Failure -- GPIHBP: Glycosylphosphatidyl Inositol Anchoring High-Density Lipoprotein Binding Protein -- GREACE: Greek Atorvastatin and Coronary Heart Disease Evaluation -- HDL: High-Density Lipoprotein -- HDL-C: High-Density Lipoprotein Cholesterol -- HeFH: Heterozygous FH -- HoFH: Homozygous FH -- HF: Heart Failure -- HIV: Human Immunodeficiency Virus -- HMG CoA reductase: 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme a Reductase -- HPS: Heart Protection Study -- HPS2-THRIVE: Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events -- HR: Hazard Ratio -- HRT: Hormone Replacement Therapy -- hsCRP: High sensitivity C-Reactive Protein -- ICH: Intracerebral Haemorrhage -- IDL: Intermediate Density Lipoprotein -- IJD: Inflammatory joint disorder -- IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial -- JBS: Joint British Society -- JELIS: Japan EPA Lipid Intervention Study -- JUPITER: Justification for the use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin -- KDIGO: Kidney Disease: Improving Global Outcomes -- LAI: Lipid Association of India -- LMF: Lipase Maturation factor -- LPL: Lipoprotein Lipase -- LDL: Low-Density Lipoprotein -- LDL-C: Low-Density Lipoprotein Cholesterol -- LDLR: Low-Density Lipoprotein Receptor -- LIPID: Long-Term Intervention with Pravastatin in Ischemic Disease -- Lp(a): Lipoprotein (a) -- LVEF: Left Ventricular Ejection Fraction -- MEDPED: Make Early Diagnosis to Prevent Early Deaths -- MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese -- MetS: Metabolic Syndrome -- MHC: Major Histocompatibility Complex -- MI: Myocardial Infarction -- mTOR: Mammalian Target Of Rapamycin -- NAFLD: Non-alcoholic Fatty Liver Disease -- NASH: Non-alcoholic Steatohepatitis -- NICE: National Institute for Health and Care Excellence -- NLA: National Lipid Association -- NNT: Number Needed to Treat -- Non-HDL-C: Non-High-density Lipoprotein Cholesterol -- NSAID: Non-Steroidal Anti-Inflammatory Drug -- NT-proBNP: N-Terminal pro-Brain Natriuretic Peptide -- NYHA: New York Heart Association -- OCP: Oral Contraceptive Pill -- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome During Treatment With Alirocumab -- PCOS: Polycystic Ovary Syndrome -- PCSK9: Proprotein Convertase Subtilisin Kexin Type 9 -- PPAR: Peroxisome Proliferator-Activated Receptor -- PRECISION: Prospective Randomised Evaluation of Celecoxib Integrated Safety VS Ibuprofen or Naproxen -- PROSPER: Prospective Study of Pravastatin in the Elderly at Risk -- PsA: Psoriatic Arthritis -- RA: Rheumatoid Arthritis -- RCT: Randomised Controlled Trial -- RR: Relative Risk -- SAGE: Study Assessing Goals in the Elderly -- SHEP: Systolic Hypertension in the Elderly Program -- T2DM: Type 2 DiabetesMellitus -- TG: Triglyceride -- THRaST: THRombolysis and STatins -- TNT: Treating to New Targets -- TRACE-RA: Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with RA -- tsDMARDs: Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs -- TSH: Thyroid Stimulating Hormone -- ULN: Upper Limit of Normal -- VLDL: Very Low-density Lipoprotein -- VLDL-C: Very Low-density Lipoprotein cholesterol -- WHO: World Health Organization -- WOSCOPS: West of Scotland Coronary Prevention Study; Lipids -- Periodicals; 616.3997
• DOI: 10.1080/17584299.2017.1383700
• Languages: English
• ISSNs: 1758-4299

Abstract

ABSTRACT: These Lipid Association of India (LAI) recommendations refer to specific patient populations. They follow the previously published LAI part 1 recommendations. These part 2 LAI recommendations focus on specific patient groups. These include patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection. We also consider women, the elderly and post-transplantation patients. The current recommendations are based, as much as possible, on available data from Indian populations.